Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]

Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone...

Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA

Depth of response to daratumumab, lenalidomide, bortezomib, and dexamethasone improves over time in transplant-eligible newly diagnosed multiple myeloma ( Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA )

CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in...

Prof Deepu Madduri - Mount Sinai, New York, USA

CARTITIUDE-1: BCMA-targeted CAR T-cell therapy shows high response rates in patients with multiple myeloma ( Prof Deepu Madduri - Mount Sinai, New York, USA )

Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse...

Dr Patrick Brown - Johns Hopkins University, Baltimore, USA

Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse of B-ALL in children and adolescents ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )

Identifying prognostic constellations of driver mutations in acute myeloid...

Dr Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA

Identifying prognostic constellations of driver mutations in acute myeloid leukaemia and myelodysplastic syndromes ( Dr Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA )

CANDOR: Triple drug combo delays disease progression in stubborn multiple...

Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

CANDOR: Triple drug combo delays disease progression in stubborn multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )

Maintenance therapy with CC-486 for acute myeloid leukaemia

Prof Andrew Wei - Monash University, Melbourne, Australia

Maintenance therapy with CC-486 for acute myeloid leukaemia ( Prof Andrew Wei - Monash University, Melbourne, Australia )

Daratumuab, carfilzomib and dexamethasone increases survival in patients with...

Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

$Daratumuab, carfilzomib and dexamethasone increases survival in patients with relapsed/refractory multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )$

Exploring the pathogenesis of AML and myelodysplastic syndromes using genome...

Dr Ilaria Iacobucci - St. Jude Children's Research Hospital, Memphis, USA

Exploring the pathogenesis of AML and myelodysplastic syndromes using genome and transcriptome sequencing ( Dr Ilaria Iacobucci - St. Jude Children's Research Hospital, Memphis, USA )

QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients...

Prof Andrew Wei - Monash University, Melbourne, Australia

QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients with acute myeloid leukaemia in first remission ( Prof Andrew Wei - Monash University, Melbourne, Australia )

Blinatumomab demonstrates superior efficacy compared to chemotherapy in...

Dr Patrick Brown - Johns Hopkins University, Baltimore, USA

Blinatumomab demonstrates superior efficacy compared to chemotherapy in children and young adults with relapsed B-ALL ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )

Multiple myeloma highlights from ASH 2019

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

Multiple myeloma highlights from ASH 2019 ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )

MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed...

Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia

$MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed/refractory chronic lymphocytic leukaemia ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )$

More from ecancer